Introduction Nevoid Basal Cell Carcinoma Syndrome (NBCCS), also known as Gorlin Syndrome, is a rare genetic disorder characterized by the development of multiple basal cell carcinomas (BCCs), jaw cysts, and skeletal abnormalities. Managing the numerous BCCs associated with NBCCS presents a significant clinical challenge. HeberFERON, a novel therapeutic formulation combining interferon alpha-2b and interferon gamma,...
AllCardiovascularChild DevelopmentCuba’s AchievementsCubaHeal NewsDermatologyEducationEndocrinologyGeriatricGynecologyInternational CollaborationMedical (General)NeurologyOncologyOphthalmologyOrthopedicPsychiatrySubstance Abuse RehabilitationTravel InsuranceUncategorized
Introduction Skin cancer is one of the most prevalent cancers worldwide, with cases continuing to rise due to increased exposure to ultraviolet (UV) radiation and other environmental factors. Among the different types of skin cancer, basal cell carcinoma (BCC) and squamous cell carcinoma (SCC) are the most common. Traditional treatments often involve surgical excision, which...
Introduction Non-small cell lung cancer (NSCLC) accounts for approximately 85% of all lung cancer cases, making it a significant global health concern. Traditional treatments include surgery, chemotherapy, and radiation therapy; however, these approaches often have limited efficacy, especially in advanced stages. In response to this challenge, researchers have developed Racotumomab, a therapeutic vaccine designed to...
Cimavax-EGF for Non-small Cell Lung Cancer Vaccine Cimavax-EGF is the first worldwide registered therapeutic vaccine for non-small lung cancer developed in Cuba by the Center for Molecular Immunology in conjunction with the Center for Genetic Engineering and Biotechnology. In 2008 it was approved by the Cuban regulatory authority for the use in adults with advanced...
The recommended dose of CIMAher® is 200 mg given once a week for 6 weeks concomitant with radiotherapy and / or radio-chemotherapy. Subsequently, dose of 200 mg every 15 days (maintenance dose) until the general condition of the patient allows it.